Home LiteratureArticle Details
PMID: 12808151 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.

Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J

Abstract

The influence of transforming growth factor beta (TGF-beta) signaling on Neu-induced mammary tumorigenesis and metastasis was examined with transgenic mouse models. We generated mice expressing an activated TGF-beta type I receptor or dominant negative TGF-beta type II receptor under control of the mouse mammary tumor virus promoter. When crossed with mice expressing activated forms of the Neu receptor tyrosine kinase that selectively couple to the Grb2 or Shc signaling pathways the activated type I receptor increased the latency of mammary tumor formation but also enhanced the frequency of extravascular lung metastasis. Conversely, expression of the dominant negative type II receptor decreased the latency of Neu-induced mammary tumor formation while significantly reducing the incidence of extravascular lung metastases. These observations argue that TGF-beta can promote the formation of lung metastases while impairing Neu-induced tumor growth and suggest that extravasation of breast cancer cells from pulmonary vessels is a point of action of TGF-beta in the metastatic process.

MeSH Terms
Activin Receptors, Type I/genetics,physiology Adaptor Proteins, Signal Transducing Adaptor Proteins, Vesicular Transport Animals Apoptosis Drosophila Proteins Female GRB2 Adaptor Protein Genes, Dominant Genes, erbB-2 Humans Lactation Ligases/antagonists & inhibitors,physiology Lung Neoplasms/etiology,secondary Mammary Glands, Animal/growth & development Mammary Neoplasms, Experimental/prevention & control Mice Mice, Transgenic Mitotic Index Neoplasm Proteins/antagonists & inhibitors,physiology Nerve Tissue Proteins/antagonists & inhibitors,physiology Pregnancy Protein Serine-Threonine Kinases Proteins/antagonists & inhibitors,physiology Receptor, Transforming Growth Factor-beta Type I Receptor, Transforming Growth Factor-beta Type II Receptors, Transforming Growth Factor beta/genetics,physiology Sequence Deletion Shc Signaling Adaptor Proteins Signal Transduction Src Homology 2 Domain-Containing, Transforming Protein 1 Time Factors Transforming Growth Factor beta/pharmacology,physiology Tumor Cells, Cultured Ubiquitin-Protein Ligases
Chemicals
Adaptor Proteins, Signal Transducing Adaptor Proteins, Vesicular Transport Drosophila Proteins GRB2 Adaptor Protein GRB2 protein, human Grb2 protein, mouse Neoplasm Proteins Nerve Tissue Proteins Proteins Receptors, Transforming Growth Factor beta SHC1 protein, human Shc Signaling Adaptor Proteins Shc1 protein, mouse Src Homology 2 Domain-Containing, Transforming Protein 1 Transforming Growth Factor beta Ubiquitin-Protein Ligases neur protein, Drosophila Protein Serine-Threonine Kinases Activin Receptors, Type I Receptor, Transforming Growth Factor-beta Type I Receptor, Transforming Growth Factor-beta Type II Ligases
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Siegel Peter M
Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Shu Weiping
Cardiff Robert D
Muller William J
Massagué Joan
References (38)
38 references, click to expand
  1. The role for transforming growth factor-beta (TGF-beta) in human cancer.
    Crit Rev Oncog. 1999;10(4):303-60 PMID: 10654929
  2. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion.
    Cell Growth Differ. 1998 May;9(5):393-404 PMID: 9607560
  3. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.
    Mol Cell Biol. 2001 Mar;21(5):1540-51 PMID: 11238891
  4. Transforming growth factor-beta and breast cancer: Lessons learned from genetically altered mouse models.
    Breast Cancer Res. 2000;2(2):100-6 PMID: 11250699
  5. TGF-beta signaling in tumor suppression and cancer progression.
    Nat Genet. 2001 Oct;29(2):117-29 PMID: 11586292
  6. Instantaneous evaluation of mammalian cell culture growth rates through analysis of the mitotic index.
    J Biotechnol. 2002 Apr 25;95(1):63-84 PMID: 11879713
  7. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    J Clin Invest. 2002 Jun;109(12):1551-9 PMID: 12070302
  8. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
    J Clin Invest. 2002 Jun;109(12):1607-15 PMID: 12070308
  9. Dissemination and growth of cancer cells in metastatic sites.
    Nat Rev Cancer. 2002 Aug;2(8):563-72 PMID: 12154349
  10. Lobulo-alveolar development of mouse mammary glands is regulated by thyroid hormones.
    Endocrinology. 1979 Feb;104(2):409-18 PMID: 109279
  11. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
    Cell. 1988 Jul 1;54(1):105-15 PMID: 2898299
  12. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene.
    Cell. 1989 Jun 16;57(6):931-6 PMID: 2567634
  13. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
    Mol Cell Biol. 1992 Mar;12(3):954-61 PMID: 1312220
  14. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.
    Eur J Cancer. 1992;28(2-3):641-4 PMID: 1317202
  15. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
    J Cell Biol. 1992 Nov;119(3):493-501 PMID: 1400587
  16. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
    Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 PMID: 1359541
  17. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.
    Cancer Res. 1992 Dec 15;52(24):6949-52 PMID: 1458485
  18. Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation.
    EMBO J. 1993 May;12(5):1835-45 PMID: 8491177
  19. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region.
    Mol Cell Biol. 1993 Dec;13(12):7239-47 PMID: 8246946
  20. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1.
    Genes Dev. 1993 Dec;7(12A):2308-17 PMID: 8253379
  21. The biology of erbB-2/neu/HER-2 and its role in cancer.
    Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84 PMID: 7819273
  22. Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex.
    Mol Cell Biol. 1995 Mar;15(3):1573-81 PMID: 7862150
  23. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex.
    EMBO J. 1995 May 15;14(10):2199-208 PMID: 7774578
  24. FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors.
    J Biol Chem. 1996 Sep 20;271(38):22941-4 PMID: 8798476
  25. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.
    Genes Dev. 1996 Oct 1;10(19):2462-77 PMID: 8843198
  26. Mechanism of TGFbeta receptor inhibition by FKBP12.
    EMBO J. 1997 Jul 1;16(13):3866-76 PMID: 9233797
  27. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.
    Mol Cell Biol. 1997 Sep;17(9):5410-25 PMID: 9271418
  28. Apoptosis in mouse embryos: elevated levels in pregastrulae and in the distal anterior region of gastrulae of normal and mutant mice.
    Dev Dyn. 1998 Nov;213(3):293-308 PMID: 9825865
  29. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
    J Clin Invest. 1999 Jan;103(2):197-206 PMID: 9916131
  30. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12.
    Cell. 1999 Feb 5;96(3):425-36 PMID: 10025408
  31. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.
    EMBO J. 1999 Apr 15;18(8):2149-64 PMID: 10205169
  32. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.
    Clin Exp Metastasis. 1999 Feb;17(1):27-34 PMID: 10390144
  33. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype.
    Int J Cancer. 1999 Oct 8;83(2):255-62 PMID: 10471536
  34. TGFbeta signaling in growth control, cancer, and heritable disorders.
    Cell. 2000 Oct 13;103(2):295-309 PMID: 11057902
  35. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
    Cancer Res. 1997 Dec 15;57(24):5564-70 PMID: 9407968
  36. Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis.
    Mol Cell Biol. 1998 Apr;18(4):2344-59 PMID: 9528804
  37. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
    Cell Growth Differ. 1998 Mar;9(3):229-38 PMID: 9543389
  38. Regulation of immune responses by TGF-beta.
    Annu Rev Immunol. 1998;16:137-61 PMID: 9597127
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2003-07-08
Epub
2003-00-13
Pages
8430-5
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC166246
Subset
IM
Grants
NCI NIH HHS · P01 CA094060 · United States
NCRR NIH HHS · U42 RR014905 · United States
NCI NIH HHS · P01-CA94060 · United States
NCRR NIH HHS · U42-RR14905 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com